The Trials and Tribulations of Vitamin C

Journal of Orthomolecular Medicine

Volumn 18, Issue 3-4, 2003, Pages 173-186

  Lawson, Stephen ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEMOLYSIS; HUMAN; INFECTION; IRON OVERLOAD; META ANALYSIS; NEPHROLITHIASIS; PROPHYLAXIS; REVIEW; SIDE EFFECT; VITAMIN SUPPLEMENTATION;

EID: 0142054099     PISSN: 03170209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Haworth WN, Hirst EL: Synthesis of ascorbic acid. J Soc Chem Ind, 1933; 52: 645-647.
2. Frei B, England L, Ames BN: Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA, 1989; 86(16): 6377-6381.
3. Buettner GR: The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys, 1993; 300(2): 535-543.
4. Zhu B-Z, Frei B: Biochemical and physiological interactions of vitamin C and iron: pro- or antioxidant? In eds. Packer L, Traber MG, Kraemer K, et al. The Antioxidant Vitamins C and E. Champaign, IL, AOCS Press, 2002; 32-49.
5. Rivers JM: Safety of high-level vitamin C ingestion. In eds. Burns JJ, Rivers JM, and Machlin LJ. Third Conference on Vitamin C. Annals of the New York Academy of Sciences. New York, NY, 1987; 498: 445-454.
6. Bendich A: Vitamin C safety in humans. In eds. Packer L and Fuchs J. Vitamin C in Health and Disease. New York, NY, Marcel Dekker, Inc., 1997; 367-379.
7. A Report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes; Food and Nutrition Board, Institute of Medicine: Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC, National Academy Press, 2000.
8. Johnston CS: Potential adverse effects of vitamins C and E. In eds. Packer L, Traber MG, Kraemer K, et al. The Antioxidant Vitamins C and E. Champaign, IL, AOCS Press, 2002; 116-132.
9. Expert Group on Vitamins and Minerals: Safe Upper Levels for Vitamins and Minerals. Food Standards Agency. London, England. May 2003.
10. Johnston CS: Biomarkers for establishing a tolerable upper intake level for vitamin C Nutr Rev, 1999; 57(3): 71-77.
11. Curhan GC, Willett WC, Rimm EB, et al: A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol, 1996; 155(6): 1847-1851.
12. Curhan GC, Willett WC, Speizer FE, et al: Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol, 1999; 10: 840-845.
13. U. S. Preventive Services Task Force: Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale. Ann Intern Med 2003; 139(1): 51-55.
14. Morris CD, Carson S: Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med, 2003; 139(1): 56-70.
15. Pauling L: Vitamin C and the Common Cold. San Francisco, CA, W. H. Freeman, 1970.
16. Pauling L: How to Live Longer and Feel Better. New York, NY, W. H. Freeman, 1986.
17. Stone I: The Healing Factor: Vitamin C Against Disease. New York, NY, Grosset & Dunlap, 1972.
18. Werbach MR: Nutritional Influences on Illness: A Sourcebook of Clinical Research. Tarzana, CA, Third Line Press, 1987.
19. Hoffer A, Pauling L: Vitamin C & Cancer: Discovery, Recovery, Controversy. Kingston, Ontario, Canada, Quarry Press Inc., 2001.
20. Sheffrey S: Vitamin C: How Best to Use It. Ann Arbor, MI, Stephen Sheffrey. 2000.
21. Levy TE: Vitamin C, Infectious Diseases, and Toxins: Curing the Incurable. Xlibris Corp., 2002.
22. Hemilä H: Does vitamin C alleviate the symptoms of the common cold? A review of current evidence. Scand J Infect Dis, 1994;26:1-6.
23. Hemilä H: Vitamin C and infectious diseases. In eds. Packer L and Fuchs J. Vitamin C in Health and Disease. New York, NY, Marcel Dekker, Inc., 1997; 471-503.
24. Klenner FR: Massive doses of vitamin C and the viral diseases. South Med Surg, 1951;113:101-107.
25. Cathcart RF: Vitamin C: the nontoxic, nonrate-limited, antioxidant free radical scavenger. Med Hypotheses, 1985; 18(1): 61-77.
26. Harakeh S, Jariwalla RJ, Pauling L: Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. Proc Natl Acad Sci, USA, 1990; 87: 7245-7249.
27. Podmore ID, Griffiths HR, Herbert KE, et al: Vitamin C exhibits pro-oxidant properties. Nature, 1998; 392: 559.
28. European Standards Committee on Oxidative DNA Damage: Comparison of different methods of measuring 8-oxoguanine as a marker of oxidative DNA damage. Free Radic Res, 2000; 32: 333-341.
29. Levine M, Conry-Cantilena C, Wang Y, et al: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996; 93: 3704-3709.
30. Levine M, Wang Y, Padayatty SJ, et al: A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA, 2001; 98(17): 9842-9846.
31. Schneider M, Diemer K, Engelhart K, et al: Protective effects of vitamins C and E on the number of micronuclei in lymphocytes in smokers and their role in ascorbate free radical formation in plasma. Free Radic Res, 2001; 34(3): 209-219.
32. Proteggente AR, Rehman A, Halliwell B, et al: Potential problems of ascorbate and iron supplementation: pro-oxidant effect in vivo? Biochem Biophys Res Commun, 2000; 277(3): 535-540.
33. Lee SH, Oe T, Blair IA: Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science, 2001; 292: 2083-2086.
34. Sattler W, Maiorino M, Stocker R: Reduction of HDL- and LDL-associated cholesterylester and phospholipid hydroperoxides by phospholipid hydroperoxide glutathione peroxidase and Ebselen (PZ 51). Arch Biochem Biophys, 1994; 309(2): 214-221.
35. Zamburlini A, Maiorino M, Barbera P, et al: Measurement of lipid hydroperoxides in plasma lipoproteins by a new highly-sensitive 'single photon counting' luminometer. Biochim Biophys Acta, 1995; 1256: 233-240.
36. Suh J, Zhu B-Z, Frei B: Ascorbate does not act as a pro-oxidant towards lipids and proteins in human plasma exposed to redox-active transition metal ions and hydrogen peroxide. Free Radic Biol Med, 2003; 34(10): 1306-1314.
37. Chen K, Suh J, Carr AC, et al: Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron-overload. Am J Physiol Endocrinol Metab, 2000; 279: E1406-E1412.
38. Dwyer JH, Nicholson LM, Shirecore A, et al: Vitamin C supplement intake and progression of carotid atherosclerosis, the Los Angeles Atherosclerosis Study. 40th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, La Jolla, CA, 2000.
39. Kritchevsky SB, Shimakawa T, Tell GS, et al: Dietary antioxidants and carotid artery wall thickness. Circulation, 1995; 92: 2142-2150.
40. Fang JC, Kinlay S, Beltrame J, et al: Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomized trial. Lancet, 2002; 359: 1108-1113.
41. Salonen RM, Nyyssonen K, Kaikkonen J, et al: Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression. Circulation, 2003; 107: 947-953.
42. Salonen JT, Nyyssonen K, Salonen R, et al: Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med, 2000; 248: 377-386.
43. Brown BG, Zhao, X-Q, Chait, A, et al: Simvistatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med, 2001; 345(22): 1583-1592.
44. Osganian SK, Stampfer MJ, Rimm E, at al: Vitamin C and the risk of coronary heart disease in women. J Am Coll Cardiol 2003; 42(2): 246-252.
45. Langlois M, Duprez D, Delanghe J, et al: Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation, 2001; 103: 1863-1868.
46. Bruunsgaard H, Poulsen HE, Pedersen BK, et al: Long-term combined supplementations with alpha-tocopherol and vitamin C have no detectable anti-inflammatory effects in healthy men. J Nutr, 2003; 133(4): 1170-1173.
47. Carr AC, Frei B: Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr, 1999; 69: 1086-1107.
48. Enstrom JE, Kanim LE, Klein MA: Vitamin C intake and mortality among a sample of the United States population. Epidemiology, 1992; 3: 194-202.
49. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol, 2001; 119(10): 1439-1452
50. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119(10): 1417-1436.
51. Kuo ET: Effect of vitamin C on blood parameters of hypertensive subjects. J Okla State Med Assoc, 1984; 77: 177-182.
52. Osilesi O, Trout DL, Ogunwole JO, et al. Blood pressure and plasma lipids during ascorbic acid supplementation in borderline hypertensive and normotensive adults. Nutr Res, 1991; 11: 405-412.
53. Duffy SJ, Gokce N, Holbrook M, et al: Treatment of hypertension with ascorbic acid. Lancet, 1999; 354: 2048-2049.
54. Hajjar IM, George V, Sasse EA, et al: A randomized, double-blind, controlled trial of vitamin C in the management of hypertension and lipids. Am J Ther, 2002; 9(4): 289-293.
55. Darko D, Dornhorst A, Kelly FJ, et al: Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. Clin Sci. (Lond.), 2002; 103(4): 339-344.
56. Block G, Mangels AR, Norkus EP, et al: Ascorbic acid status and subsequent diastolic and systolic blood pressure. Hypertension, 2001; 37: 261-267.
57. Pauling L: Case report: lysine/ascorbate-related amelioration of angina pectoris. J Orthomol Med, 1991; 6(3&4): 144-146.
58. McBeath M, Pauling L: A case history: lysine/ ascorbate-related amelioration of angina pectoris. J Orthomol Med, 1993; 8(2): 77-78.
59. Pauling L: Third case report on lysine-ascorbate amelioration of angina pectoris. J Orthomol Med, 1993; 8(3): 137-138.
60. Nathens AB, Neff MJ, Jurkovich GJ, et al: Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg, 2002; 236(6): 814-822.
61. Nualart FJ, Rivas CI, Montecinos VP, et al: Recycling of vitamin C by a bystander effect. J Biol Chem, 2003; 278(12): 10128-10133.
62. Agus DB, Vera JC, Golde DW: Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res, 1999; 59: 4555-4558.
63. Dhariwal KR, Hartzell WO, Levine M: Ascorbic acid and dehydroascorbic acid measurements in human plasma and serum. Am J Clin Nutr 1991; 54(4): 712-716.
64. Michels AJ, Joisher N, Hagen TM: Age-related decline of sodium-dependent ascorbic acid transport in isolated rat hepatocytes. Arch Biochem Biophys, 2003; 410(1): 112-120.
65. Tsukaguchi H, Tokui T, Mackenzie B, et al: A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature, 1999; 399: 70-75.
66. Liang WJ, Johnson D, Jarvis SM: Vitamin C transport systems of mammalian cells. Mol Membr Biol, 2001; 18(1): 87-95.
67. Agus DB, Gambhir SS, Pardridge WM, et al: Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest, 1997; 100(11): 2842-2848.
68. Tsao C Young M: Molecular structure-dependent cytotoxic effect of ascorbate derivatives. In Vitro Cell Devel Biol, 1995; 31: 87-90.
69. Kimoto E, Tanaka H, Gyotoku J, et al: Enhancement of antitumor activity of ascorbate against Ehrlich ascites tumor cells by the copper: glycylglycylhistidine complex. Cancer Res, 1983; 43(2): 824-828.
70. Morishige F: Studies on the role of large dosage of vitamin C in the orthomolecular nutritional treatments of cancer. Nakamura Memorial Hospital, Fukuoka, Japan, ca 1983.
71. Leung PY, Dunham WB, Tsao CS: Ascorbic acid with cupric ions as a chemotherapy for human lung tumor xenografts implanted beneath the renal capsule of immunocompetent mice. In Vivo, 1992; 6(1): 33-40.
72. Tsao C, Dunham W, Leung P: Growth control of human colon tumor xenografts by ascorbic acid, copper, and iron. Cancer J, 1995; 8: 157-163.
73. Prasad KN, Kumar A, Kochupillai VK, et al: High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr, 1999; 18(1): 13-25.
74. Prasad KN, Cole WC, Kumar B, et al: Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutr, 2001; 20(5): 450S-463S.
75. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci. USA, 1978; 75(9): 4538-4542.
76. Hoffer A, Pauling L: Hardin Jones biostatistical analysis of mortality data for a second set of cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomol Med, 1993; 8(3): 157-167.
77. Riordan NH, Riordan HD, Casciari JP: Clinical and experimental experiences with intravenous vitamin C. J Orthomol. Med, 2000; 15(4): 201-213.
78. Jaakkola K, Lahteenmaki P, Laakso J, et al: Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res, 1992; 12(3): 599-606.
79. Padayatty SJ, Levine M: Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr, 2000; 19(4): 423-425.
80. Creagan ET, Moertel CG, O'Fallon JR, et al: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Engl J Med, 1979; 301: 687-690.
81. Moertel CG, Fleming TR, Creagan ET, et al: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Engl J Med, 1985; 312: 137-141.
82. Tamayo C, Richardson MA: Vitamin C as a cancer treatment: state of the science and recommendations for research. Altern Ther, 2003; 9(3): 94-102.
83. Pauling L, Nixon JC, Stitt F, et al: Effect of dietary ascorbic acid on the incidence of spontaneous mammary tumors in RIII mice. Proc Natl Acad Sci USA, 1985; 82: 5185-5189.
84. Dunham WB, Zuckerkandl E, Reynolds R, et al: Effects of intake of L-ascorbic acid on the incidence of dermal neoplasms induced in mice by ultraviolet light. Proc Natl Acad Sci USA, 1982; 79: 7532-7536.
85. Pauling L, Willoughby R, Reynolds R, et al: Incidence of squamous cell carcinoma in hairless mice irradiated with ultraviolet light in relation to intake of ascorbic acid (vitamin C) and of D, L-alpha-tocopheryl acetate (vitamin E). In Hanck A, ed. Vitamin C: New Clinical Applications in Immunology, Lipid Metabolism, and Cancer. International Journal for Vitamin and Nutrition Research Supplement No. 23. Bern, Germany, Hans Huber Publishers, 1982; 53-82.
86. Kübler W, Gehler J: Zur kinetik der enteralen ascorbinsä ure-resorption ein beitrag zur berechnung nicht dosisproportionaler resorption svorgänge. Intl Z Vit Forschung 1970; 40: 442-453.
87. Gehler J, Kubler W: Verteilungsstudien mit intravenös infundierter ascorbinsäure. Intl Z Vit Forschung, 1970; 40: 454-464.
88. Brubacher D, Moser U, Jordan P: Vitamin C concentrations in plasma as a function of intake: a meta-analysis. Int J Vitam Nutr Res, 2000; 70(5): 226-237.
89. Dawson EB, Evans DR, Harris WA, et al: The effect of ascorbic acid supplementation on the blood lead levels of smokers. J Am Coll Nutr, 1999; 18(2): 166-170.
90. Cheng Y, Willett WC, Schwartz J, et al: Relation of nutrition to bone lead and blood lead levels in middle-aged to elderly men. The Normative Aging Study. Am J Epidemiol, 1998; 147(12): 1162-1174.
91. Johnston CS, Retrum KR, and Srilakshmi JC: Antihistamine effects and complications of supplemental vitamin C. J Am Diet Assoc, 1992; 92: 988-989.
92. Smith AB, Visioli F, Hagen TM: Vitamin C matters: increased oxidative stress in cultured human aortic endothelial cells without supplemental ascorbic acid. FASEB J, 2002; 16(9): 1102-1104.
93. Tsao CS, Leung PY, Young M: Effect of dietary ascorbic acid intake on tissue vitamin C in mice. J Nutr, 1987; 117(2): 291-297.
94. Dunham WB, Young M, Tsao CS: Interference by bedding materials in animal test systems involving ascorbic acid depletion. Lab Anim Sci, 1994; 44(3): 283-285.
95. Netke SP, Roomi MW, Tsao C, et al. Ascorbic acid protects guinea pigs from acute aflatoxin toxicity. Toxicol Appl Pharmacol, 1997; 143(2): 429-435.
96. Dunham WB, Tsao C, Barth R, et al: Protection by dietary ascorbate of guinea pigs from neurolathyrism. Nutr Res, 1995; 15: 993-1004.
97. Wakimoto P, Block G: Dietary intake, dietary patterns, and changes with age: an epidemiological perspective. J Geront A Biol Sci Med Sci, 2001; 56 Spec. No. 2(2): 65-80.